Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lux Bioscience Brings In $50 Million To Take Luveniq To The Finish Line Alone

This article was originally published in The Pink Sheet Daily

Executive Summary

The ophthalmology specialist's inside round could take it through to launch of its lead product--or act as leverage in deal negotiations.

You may also be interested in...



Luveniq Advisory Committee: Renal Side Effects May Be Key Issue With Immunosuppressant

Lux Biosciences' Luveniq (voclosporin) for uveitis will undergo review by FDA's Dermatologic and Ophthalmic Drugs Advisory Committee on June 28.

Luveniq Advisory Committee: Renal Side Effects May Be Key Issue With Immunosuppressant

Lux Biosciences' Luveniq (voclosporin) for uveitis will undergo review by FDA's Dermatologic and Ophthalmic Drugs Advisory Committee on June 28.

Financings Of The Fortnight: Despite Venture Capital Fundraising Struggles, Deals Continue

Big venture rounds for Flexion and Lux Biosciences highlight the last two weeks' financing activity.

Topics

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel